A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Moderate to Severe Atopic Dermatitis
Latest Information Update: 21 Nov 2025
At a glance
- Drugs JNJ 95597528 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms READY-AD
- Sponsors Janssen Research & Development
Most Recent Events
- 21 Nov 2025 New trial record